The PI3Kα-specific inhibitor alpelisib, has shown activity in PIK3CA-mutant breast cancers (NCT02437318) and recently granted FDA and European commission approval, while its potential in the regression and stabilisation of progressive BCBM has been highlighted [39, 40]. This evidence concerns the gene PIK3CA and breast carcinoma.